Last Subject Completed Dosing In Vaxart's Phase 2 Trial Of Its Oral Pill Bivalent Norovirus Vaccine Candidate. No Vaccine-Related Serious Adverse Events Reported; Topline Data From Two Phase 2 Norovirus Vaccine Studies Expected Over The Next 3 Months
Portfolio Pulse from Benzinga Newsdesk
Vaxart has completed dosing in its Phase 2 trial of the oral pill bivalent norovirus vaccine candidate, with no serious adverse events reported. Topline data from two Phase 2 norovirus vaccine studies are expected in the next 3 months.
June 06, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart's Phase 2 trial of its oral norovirus vaccine candidate has completed dosing with no serious adverse events. Topline data from two studies expected in the next 3 months.
The completion of dosing in Vaxart's Phase 2 trial without any serious adverse events is a positive development for the company. The upcoming topline data from the two studies could potentially have a significant impact on the stock price, depending on the results. This news is highly relevant and important for investors in Vaxart, and the confidence in the analysis is high.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100